These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36528447)

  • 41. A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters.
    Frantz PN; Barinov A; Ruffié C; Combredet C; Najburg V; de Melo GD; Larrous F; Kergoat L; Teeravechyan S; Jongkaewwattana A; Billon-Denis E; Tournier JN; Prot M; Levillayer L; Conquet L; Montagutelli X; Tichit M; Hardy D; Fernandes P; Strick-Marchand H; Di Santo J; Simon-Lorière E; Bourhy H; Tangy F
    Nat Commun; 2021 Nov; 12(1):6277. PubMed ID: 34725327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spike mutation D614G alters SARS-CoV-2 fitness.
    Plante JA; Liu Y; Liu J; Xia H; Johnson BA; Lokugamage KG; Zhang X; Muruato AE; Zou J; Fontes-Garfias CR; Mirchandani D; Scharton D; Bilello JP; Ku Z; An Z; Kalveram B; Freiberg AN; Menachery VD; Xie X; Plante KS; Weaver SC; Shi PY
    Nature; 2021 Apr; 592(7852):116-121. PubMed ID: 33106671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.
    Tostanoski LH; Wegmann F; Martinot AJ; Loos C; McMahan K; Mercado NB; Yu J; Chan CN; Bondoc S; Starke CE; Nekorchuk M; Busman-Sahay K; Piedra-Mora C; Wrijil LM; Ducat S; Custers J; Atyeo C; Fischinger S; Burke JS; Feldman J; Hauser BM; Caradonna TM; Bondzie EA; Dagotto G; Gebre MS; Jacob-Dolan C; Lin Z; Mahrokhian SH; Nampanya F; Nityanandam R; Pessaint L; Porto M; Ali V; Benetiene D; Tevi K; Andersen H; Lewis MG; Schmidt AG; Lauffenburger DA; Alter G; Estes JD; Schuitemaker H; Zahn R; Barouch DH
    Nat Med; 2020 Nov; 26(11):1694-1700. PubMed ID: 32884153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.
    Sun W; Leist SR; McCroskery S; Liu Y; Slamanig S; Oliva J; Amanat F; Schäfer A; Dinnon KH; García-Sastre A; Krammer F; Baric RS; Palese P
    EBioMedicine; 2020 Dec; 62():103132. PubMed ID: 33232870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
    Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
    Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
    Imai M; Halfmann PJ; Yamayoshi S; Iwatsuki-Horimoto K; Chiba S; Watanabe T; Nakajima N; Ito M; Kuroda M; Kiso M; Maemura T; Takahashi K; Loeber S; Hatta M; Koga M; Nagai H; Yamamoto S; Saito M; Adachi E; Akasaka O; Nakamura M; Nakachi I; Ogura T; Baba R; Fujita K; Ochi J; Mitamura K; Kato H; Nakajima H; Yagi K; Hattori SI; Maeda K; Suzuki T; Miyazato Y; Valdez R; Gherasim C; Furusawa Y; Okuda M; Ujie M; Lopes TJS; Yasuhara A; Ueki H; Sakai-Tagawa Y; Eisfeld AJ; Baczenas JJ; Baker DA; O'Connor SL; O'Connor DH; Fukushi S; Fujimoto T; Kuroda Y; Gordon A; Maeda K; Ohmagari N; Sugaya N; Yotsuyanagi H; Mitsuya H; Suzuki T; Kawaoka Y
    Proc Natl Acad Sci U S A; 2021 Jul; 118(27):. PubMed ID: 34140350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
    Corbett KS; Werner AP; Connell SO; Gagne M; Lai L; Moliva JI; Flynn B; Choi A; Koch M; Foulds KE; Andrew SF; Flebbe DR; Lamb E; Nurmukhambetova ST; Provost SJ; Bock KW; Minai M; Nagata BM; Ry AV; Flinchbaugh Z; Johnston TS; Mokhtari EB; Mudvari P; Henry AR; Laboune F; Chang B; Porto M; Wear J; Alvarado GS; Boyoglu-Barnum S; Todd JM; Bart B; Cook A; Dodson A; Pessaint L; Steingrebe K; Elbashir S; Sriparna M; Pekosz A; Andersen H; Wu K; Edwards DK; Kar S; Lewis MG; Boritz E; Moore IN; Carfi A; Suthar MS; McDermott A; Roederer M; Nason MC; Sullivan NJ; Douek DC; Graham BS; Seder RA
    Nat Immunol; 2021 Oct; 22(10):1306-1315. PubMed ID: 34417590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding.
    Trimpert J; Dietert K; Firsching TC; Ebert N; Thi Nhu Thao T; Vladimirova D; Kaufer S; Labroussaa F; Abdelgawad A; Conradie A; Höfler T; Adler JM; Bertzbach LD; Jores J; Gruber AD; Thiel V; Osterrieder N; Kunec D
    Cell Rep; 2021 Aug; 36(5):109493. PubMed ID: 34320400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
    Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
    Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals.
    Ye ZW; Ong CP; Tang K; Fan Y; Luo C; Zhou R; Luo P; Cheng Y; Gray VS; Wang P; Chu H; Chan JF; To KK; Chen H; Chen Z; Yuen KY; Ling GS; Yuan S; Jin DY
    Cell Mol Immunol; 2022 May; 19(5):588-601. PubMed ID: 35352010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus.
    Amanat F; Strohmeier S; Meade PS; Dambrauskas N; Mühlemann B; Smith DJ; Vigdorovich V; Sather DN; Coughlan L; Krammer F
    PLoS Biol; 2021 Dec; 19(12):e3001384. PubMed ID: 34914685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparative study of Wuhan-like and omicron-like variants of SARS-CoV-2 in experimental animal models].
    Leneva IA; Smirnova DI; Kartashova NP; Gracheva AV; Ivanina AV; Glubokova EA; Korchevaya ER; Pancratov AA; Trunova GV; Khokhlova VA; Svitich OA; Zverev VV; Faizuloev EB
    Vopr Virusol; 2022 Nov; 67(5):439-449. PubMed ID: 36515289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.